Views: 0 Author: Site Editor Publish Time: 2025-08-06 Origin: Site
Biocompatibility assesses how a medical material interacts with the human body. A biocompatible material should:
Not trigger toxic reactions (e.g., cell death, inflammation).
Avoid causing immune responses (e.g., allergies, foreign body reactions).
Function as intended without degrading into harmful byproducts.
Regulatory bodies require rigorous testing before a device can be approved for clinical use.
The ISO 10993 series, titled "Biological Evaluation of Medical Devices," is the global benchmark. Major sections include:
ISO 10993-1: Framework for risk-based evaluation based on device contact (skin, blood, tissue) and duration (short-term, long-term, permanent).
ISO 10993-5: Cytotoxicity testing (e.g., MTT assay) to check if materials kill cultured cells.
ISO 10993-10: Irritation & sensitization tests (e.g., skin patch tests).
ISO 10993-11: Systemic toxicity (acute/subacute effects).
ISO 10993-18: Chemical characterization (identifying leachable substances).
Follows ISO 10993 but emphasizes chemical characterization (ISO 10993-18) and toxicological risk assessment (ISO 10993-17).
USP <87> & <88>: Additional cytotoxicity and implantation tests.
Requires compliance with EN ISO 10993 under the Medical Device Regulation (MDR).
Focus on long-term implant safety (e.g., genotoxicity, carcinogenicity).
Adopts GB/T 16886 (equivalent to ISO 10993) but may require additional local testing.
| Test Type | Purpose | Methods |
|---|---|---|
| Cytotoxicity | Checks cell damage | MTT assay, agar diffusion (ISO 10993-5) |
| Sensitization | Detects allergic reactions | Guinea pig maximization test (ISO 10993-10) |
| Irritation | Evaluates skin/mucosa irritation | Rabbit skin test |
| Hemocompatibility | Assesses blood interaction | Hemolysis test (ISO 10993-4) |
| Implantation | Tests long-term tissue response | Rodent/muscle implant (ISO 10993-6) |
Reducing Animal Testing: Shift toward in vitro models (organ-on-a-chip, 3D cell cultures).
Advanced Material Analysis: Using chemical characterization (ISO 10993-18) to predict biocompatibility.
Personalized Implants: Biocompatibility assessments must adapt to patient-specific devices.
Biocompatibility standards ensure medical devices are safe for human use. Manufacturers must follow ISO 10993, along with regional regulations (FDA, MDR, NMPA). As technology evolves, so do testing methods—balancing scientific rigor with ethical considerations.
